DE4143214A1 - Synergistisch wirkende antikoerperzusammensetzung - Google Patents

Synergistisch wirkende antikoerperzusammensetzung

Info

Publication number
DE4143214A1
DE4143214A1 DE4143214A DE4143214A DE4143214A1 DE 4143214 A1 DE4143214 A1 DE 4143214A1 DE 4143214 A DE4143214 A DE 4143214A DE 4143214 A DE4143214 A DE 4143214A DE 4143214 A1 DE4143214 A1 DE 4143214A1
Authority
DE
Germany
Prior art keywords
antibody
antibodies
molar ratio
seq
il2rα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4143214A
Other languages
German (de)
English (en)
Inventor
Ulrich Dr Weidle
Werner Dr Scheuer
Brigitte Dr Kaluza
Gert Prof Dr Riethmueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE4143214A priority Critical patent/DE4143214A1/de
Priority to IE202892A priority patent/IE922028A1/en
Priority to IL102562A priority patent/IL102562A0/xx
Priority to AU23788/92A priority patent/AU2378892A/en
Priority to PCT/EP1992/001689 priority patent/WO1993001834A1/de
Publication of DE4143214A1 publication Critical patent/DE4143214A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE4143214A 1991-07-25 1991-12-30 Synergistisch wirkende antikoerperzusammensetzung Withdrawn DE4143214A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE4143214A DE4143214A1 (de) 1991-07-25 1991-12-30 Synergistisch wirkende antikoerperzusammensetzung
IE202892A IE922028A1 (en) 1991-07-25 1992-07-01 Antibody composition acting synergistically
IL102562A IL102562A0 (en) 1991-07-25 1992-07-20 Antibody composition acting synergistically
AU23788/92A AU2378892A (en) 1991-07-25 1992-07-23 Synergistic antibody composition
PCT/EP1992/001689 WO1993001834A1 (de) 1991-07-25 1992-07-23 Synergistisch wirkende antikörperzusammensetzung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4124759 1991-07-25
DE4143214A DE4143214A1 (de) 1991-07-25 1991-12-30 Synergistisch wirkende antikoerperzusammensetzung

Publications (1)

Publication Number Publication Date
DE4143214A1 true DE4143214A1 (de) 1993-01-28

Family

ID=25905832

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4143214A Withdrawn DE4143214A1 (de) 1991-07-25 1991-12-30 Synergistisch wirkende antikoerperzusammensetzung

Country Status (5)

Country Link
AU (1) AU2378892A (xx)
DE (1) DE4143214A1 (xx)
IE (1) IE922028A1 (xx)
IL (1) IL102562A0 (xx)
WO (1) WO1993001834A1 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615664A1 (en) * 2004-02-18 2006-01-18 Medexgen Inc. Pharmaceutical composition for treatment of immunological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
FR2616330B1 (fr) * 1987-06-12 1990-12-21 Immunotech Sa Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme
DE4028955A1 (de) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen den interleukin 2-rezeptor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615664A1 (en) * 2004-02-18 2006-01-18 Medexgen Inc. Pharmaceutical composition for treatment of immunological disorders
EP1615664A4 (en) * 2004-02-18 2006-12-27 Medexgen Inc PHARMACEUTICAL COMPOSITION USEFUL IN THE TREATMENT OF IMMUNOLOGICAL DISORDERS

Also Published As

Publication number Publication date
WO1993001834A1 (de) 1993-02-04
IL102562A0 (en) 1993-01-14
AU2378892A (en) 1993-02-23
IE922028A1 (en) 1993-01-27

Similar Documents

Publication Publication Date Title
DE69916807T2 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
DE69309487T2 (de) Peripheralisierung hämatopoietischer stammzellen
DE69315847T2 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE69723888T2 (de) Gemischter Chimerismus und Toleranz
DE69119278T2 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
DE69733960T2 (de) Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation
DE69426743T2 (de) Bispezifische Auslösemoleküle, die das Lymphozytantigen CD2 und Tumorantigene erkennen
DE68928915T2 (de) Immunotherapie mit einbeziehung der cd28-stimulation
DE69713499T3 (de) Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
EP0453898B1 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen
DE69533189T2 (de) Immuntherapie von krebs mit allogenen lymphocyten
DE69504955T2 (de) Immunstimulierende monoklonale antikörper
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE69231250T2 (de) Kombinierte zelluläre und immunsuppressive therapien
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE69535713T2 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
DD296843A5 (de) Monoklonale antikoerper zur indukzierung von tobranz
EP1200126B1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von virusinfektionen
EP0340604B1 (de) Monoklonaler Antikörper und seine Verwendung
DE3750235T2 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
WO2004056873A1 (de) Steigerung der immunantwort durch substanzen, welche die funktion von natürlichen killerzellen beeinflussen
DE69815840T2 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DE69429657T2 (de) Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten
DE69835591T2 (de) Induktoren für immuntoleranz

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee